Lastly, several clinical trials evaluating targeted therapy such as ALK or EGFR inhibitors in non-small cell lung cancer or BRAF inhibitors in melanoma for combination immunotherapy are currently on-going, but further investigations are needed to elucidate the precise immune-mediated mechanism of action to enhance anti-tumor immunity. This evidence concerns the gene EGFR and non-small cell lung carcinoma.